KEY POINTS
- This retrospective single-center study analyzed 72 patients with sporadic vestibular schwannoma, comparing 49 treated with staged Gamma Knife radiosurgery (GKRS) plus bevacizumab against 23 receiving single-session GKRS alone. Patients with NF2-related disease or bilateral schwannomas were excluded; the two groups were treated in different periods, 2021–2025 versus 2014–2020, with median follow-up of 18 months in each group.
- The combined-treatment cohort received 6–9 Gy per GKRS session over 2–5 sessions, separated by approximately one month, with a median cumulative prescription dose of 24 Gy. Bevacizumab started at the first GKRS session, usually at 5 mg/kg intravenously every four weeks, for a median nine cycles; the comparator received single-session GKRS at a median 13 Gy, making the radiosurgical schedules fundamentally different.
- Longitudinal tumor-volume trajectories differed significantly between treatment strategies (treatment-by-time interaction, p<0.001). Mean tumor-volume changes with staged GKRS plus bevacizumab were −27.6% at three months and −32.2% at 12 months, compared with +12.1% and +39.3%, respectively, after single-session GKRS. Greater regression with combined treatment remained significant across multiple follow-up time points after adjustment for baseline characteristics.
- Early tumor enlargement exceeding 10% occurred in 7/49 patients (14.3%) receiving combined treatment versus 14/23 (60.9%) receiving GKRS alone (HR 0.16, 95% CI 0.06–0.40; p<0.001). The association persisted after propensity-score weighting (HR 0.15, 95% CI 0.06–0.40), although such adjustment cannot eliminate unmeasured confounding or treatment-era differences.
- Confirmed pseudoprogression, defined as transient enlargement exceeding 10% followed by regression below baseline, occurred in 2/49 patients (4.1%) versus 4/23 (17.4%). Unlike the early-enlargement endpoint, this difference was not statistically significant (p=0.078). Median onset of enlargement was six months in both groups, suggesting that the combination was associated primarily with less early expansion rather than a clearly different course once enlargement occurred.
- Within the combined-treatment group, larger baseline tumor volume was associated with greater longitudinal regression (interaction p<0.001), while cystic tumors regressed more than solid tumors (interaction p<0.001). Hearing remained stable or improved in 36/49 patients (73%) receiving combined treatment versus 15/23 (65%) receiving GKRS alone, but hearing assessment was largely based on clinical records and patient reports rather than standardized serial audiometry.
- Bevacizumab-associated adverse events were predominantly CTCAE grade 1–2, including hypertension in 9/49 patients (18%), headache in 5/49 (10%), bleeding in 5/49 (10%) and fatigue in 4/49 (8%). No discontinuations were attributed to bevacizumab toxicity, but the absence of a staged-GKRS-only control group, retrospective selection, noncontemporaneous cohorts and short follow-up prevent conclusions about the independent efficacy or long-term safety of bevacizumab.
CLINICAL TAKEAWAY
Staged Gamma Knife radiosurgery combined with bevacizumab was associated with earlier tumor regression and substantially less early volumetric enlargement in sporadic vestibular schwannoma, particularly in larger or cystic tumors. However, because the comparison simultaneously changed radiation fractionation and systemic treatment, it cannot establish bevacizumab's independent benefit or support routine adoption without prospective comparative validation.